Thinking of trading PFIZER?
- 1. Pfizer pharmaceutical pipeline is promising to say the least. Overall, Pfizer has up to 15 programs with blockbuster potential that could be approved by 2022. This pipeline has already delivered five regulatory approvals in just the first four months of 2019. 2. Pfizer bought back $8.9 billion worth of its shares in the first quarter. These buybacks reduce the number of outstanding shares and increase the value of the remaining ones. The company also invests in its dividend program, with the dividend currently yielding an attractive 3. 39%. Pfizer's continued focus on repurchasing its stock and paying solid dividends should help the company deliver nice long-term total returns.
Trading CFDs involves significant risk of loss
How would you like to trade PFIZER?
- Tight spreads & reliable execution
- 70+ pre-installed indicators
- Custom indicators
- 26 time frames
- Live Sentiment data
- Chart trading
- Advanced Take Profit & Stop Loss
- Depth of Market
Trading CFDs involves significant risk of loss
- Vast selection of strategies to copy
- Efficient risk management
- Can start and stop copying at your will
- Flexible allocation of funds
- Detailed performance reports
- Full transparency & access to historical data
Copy link
Trading CFDs involves significant risk of loss
For beginners:
- Great choice of available cBots for various trading strategies and risk tolerance levels
- Simple Plug and Play functionality
For advanced traders:
- Ability to create your own cBot or custom indicator
Trading CFDs involves significant risk of loss
Trade PFIZER with Fondex. Our CFD trading platform is engineered to provide you with optimal execution speed while allowing you to access 3 different trading methods on the same interface.
1. Pfizer will soon lose patent exclusivity for its blockbuster drug Lyrica. This will weigh heavily on the company's growth throughout the rest of 2019 and into 2020. Lyrica was the source of $4.6 billion, or 8.6%, of the company's revenue last year. Pfizer expects $2. 6 billion of headwinds from LOE in 2019. 2. The market is obsessing over "Medicare for All" and other proposals being floated in advance of next year's election that could result in new pressures on drug prices. 3. Drug trials can fail and new competitors can arise.
Risk Disclaimer Fondex provides this content/feature as no more than information. In particular, no advice is intended to be provided or to be relied on as provided nor endorsed by Fondex, nor any solicitation or incentive provided to subscribe for or sell or purchase any financial instrument or to join and/or terminate any of the trading strategies. The Investor is solely responsible for the choice of the signal provider, choice of trading strategy, the choice whether to sell or purchase any financial instrument on his/her trading account and monitoring of the trading activities. All trading or investments you make must be pursuant to your own unprompted and informed self-directed position. Please keep in mind that past performance is no guarantee of future results.
For more information, please view the 'Risk Disclosure'